Intellia Therapeutics, Inc. (NTLA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Intellia Therapeutics, Inc. on October 27, 2025. The filing discloses a significant operational event regarding the company's lead product candidate, nexiguran ziclumeran (nex-z), specifically concerning its Phase 3 clinical trials.
Key Financial Metrics
This filing is a current report regarding a specific event and does not provide financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. Investors should refer to the company's most recent Form 10-K or 10-Q for financial metrics.
Material Changes and Events
- Temporary Trial Pause: The Company announced a temporary pause in dosing and screening for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nex-z.
- Triggering Event: The pause follows a report on October 24, 2025, of a patient in the MAGNITUDE trial experiencing Grade 4 liver transaminases and increased total bilirubin. The patient was dosed on September 30, 2025.
- Protocol Compliance: The adverse event met the trial's protocol-defined criteria for pausing.
- Enrollment Status: As of the filing date, more than 650 patients with ATTR-CM are enrolled in MAGNITUDE, and 47 patients with ATTRv-PN are enrolled in MAGNITUDE-2. Over 450 patients are estimated to have been dosed with nex-z.
Outlook, Risks, and Management Commentary
Management has issued forward-looking statements regarding the safety, tolerability, and efficacy of nex-z. The filing explicitly highlights significant uncertainties, including:
- The ability to resume and successfully complete the MAGNITUDE and MAGNITUDE-2 trials.
- The implications of the adverse event on the safety profile and future development of nex-z.
- Regulatory agencies' evaluation of the event and subsequent filings.
- Risks related to the company's collaboration with Regeneron Pharmaceuticals, Inc.
The Company states it undertakes no duty to update this information unless required by law.
Key Facts for Investor Verification
- Verify the specific nature and severity of the Grade 4 liver transaminase event reported on October 24, 2025.
- Monitor for updates on the timeline for resuming dosing in the MAGNITUDE and MAGNITUDE-2 trials.
- Review the impact of this pause on the projected regulatory approval timeline for nex-z.
- Check for any additional safety signals in the 450+ patients already dosed with nex-z.
- Assess the potential impact on the collaboration agreement with Regeneron Pharmaceuticals, Inc.